Andreas Saltos is an Oncology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 150 publications with 2,954 citations (h-index 18); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 33612
Telephone
813-745-7365Provider last certified this registry record 23 Mar 2026.
Clinical trials
- Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Sponsor: National Cancer Institute (NCI)
- Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20241 payment
- PFIZER INC.Program year20241 payment
- Janssen Biotech, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
37.4%Opioid Agonist14.7%Oxycodone Hcl48%Tramadol Hcl29%Morphine Sulfate Er23%Part D<11 patientsPhenothiazine9.3%Prochlorperazine Maleate100%Part D≥25 patients+ 3 more classes in this area
Cancer & immunology
17.8%Kinase inhibitor14.7%Tagrisso75%Lorbrena25%Part D<11 patientsOther antineoplastic agents3.1%Lumakras100%Part D<11 patientsMetabolism & gastrointestinal
14.7%Serotonin-3 Receptor Antagonist11.3%Ondansetron Hcl100%Part D≥28 patientsPotassium supplement3.4%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
Journal of Thoracic Oncology
2025 - Real World Safety of Tarlatamab Step-Up Dosing in Extensive Stage Small Cell Lung Cancer
Journal of Thoracic Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Hatem Soliman, MD
Moffitt Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”